Overview
- Daré began offering the prescription cream, branded Dare to Play, with pre-orders now open in 10 states via a telehealth pathway through dispensing pharmacy Medvantx.
- The product contains sildenafil and is being dispensed as a compounded medication from a 503B outsourcing facility, which means it is not an FDA‑approved finished drug.
- The company says it plans a 12-week, double-blind Phase 3 study comparing the cream to a placebo as part of its effort to secure FDA approval.
- Daré reports the topical formulation is designed to increase genital blood flow with onset in about 10 to 15 minutes and with fewer systemic side effects than oral sildenafil.
- The company frames the launch as addressing limited options for women with arousal difficulties and advises that those with heart conditions or active herpes should avoid use.